<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153146">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050490</url>
  </required_header>
  <id_info>
    <org_study_id>B322201419701</org_study_id>
    <nct_id>NCT02050490</nct_id>
  </id_info>
  <brief_title>Effect of a Symptom Diary on Symptom Care and Symptom Burden in Patients Treated With Chemotherapy: a Before-and-after-study</brief_title>
  <official_title>Effect of the Implementation of a Symptom Diary on the Symptom Care Received and the Symptom Burden Experienced by Adult Cancer Patients Treated With Chemotherapy: A Before-and-after-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flemish League against Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether the implementation of a symptom diary for reporting and
      communicating chemotherapy-related symptoms improves symptom care and decreases symptom
      burden in adult patients treated with chemotherapy.

      The hypothesis is studied using a before-and-after design. First, symptom care and symptom
      burden will be observed in a sample of patients not being offered a symptom diary. Next, the
      symptom diary will be implemented at the participating hospital and symptom care and symptom
      burden will now be observed in a new sample of chemotherapy patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>symptom distress</measure>
    <time_frame>T1 (cycle 1, day 1), T2 (cycle 2, day 1), T3 (cycle 3, day 1), T4 (cycle 5, day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>for each of 9 symptoms: how distressing was the symptom perceived by the patient? (ordinal variable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptom severity</measure>
    <time_frame>T1 (cycle 1, day 1), T2 (cycle 2, day 1), T3 (cycle 3, day 1), T4 (cycle 5, day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>for each of 9 symptoms: how severe was the symptom? (ordinal variable)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>symptom care</measure>
    <time_frame>T1 (cycle 1, day 1), T2 (cycle 2, day 1), T3 (cycle 3, day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>binary variable expressing whether the patient has received care (either medication or advice) to help with the symptom</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chemotherapy-related Symptom Burden:</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Pain</condition>
  <condition>Anorexia</condition>
  <condition>Etcetera</condition>
  <arm_group>
    <arm_group_label>Before group, no diary</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>After group, with symptom diary</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (&gt;18) patients with (any type of) cancer treated with chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18) patients with (any type of) cancer treated with chemotherapy

          -  Understanding Dutch

          -  Being able to sign Informed consent

        Exclusion Criteria:

          -  More than 3 lines of chemotherapy treatment in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Wildiers, PhD</last_name>
    <phone>+3216341314</phone>
    <email>hans.wildiers@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemarie Coolbrandt, MSc</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Vulsteke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christof Vulsteke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Annemarie Coolbrandt</investigator_full_name>
    <investigator_title>Clinical Nurse Specialistt Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
